David A. Flockhart (1952–2015) was a Scottish medical researcher who was a leader in the field of personalised medicine.[1] He was especially known for his work on factors affecting the use of tamoxifen to treat breast cancer such as variability in the level of the CYP2D6 enzyme.[2][3]

References

  1. ↑ "In death, there is life", The Economist, p. 84, 26 March 2016
  2. ↑ "David Flockhart : Obituary", Edinburgh Evening News, 3 December 2015
  3. ↑ In Memoriam, David A. Flockhart PhD, MD, Indiana University Department of Medicine, 26 November 2015


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.